Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
HLS Therapeutics Inc
T.HLS
Alternate Symbol(s):
HLTRF
Healthcare
Industrials
Auto Parts
Diversified Industrials
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central...
nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:HLS)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(8)
•••
screamer99
X
View Profile
View Bullboard History
Comment by
screamer99
on Jul 29, 2024 8:13pm
RE:BC Drug Plan
Now we know what that 400k+ (hitting the ask) trade was about last Wednesday. Took a little longer than expected for the AB Drug Plan, but now we're here. Will take several quarters for
...more
(8)
•••
screamer99
X
View Profile
View Bullboard History
Post by
screamer99
on Feb 06, 2024 12:24pm
BC Drug Plan
Discussion boards are dead everywhere I can see, but the reimbursement from BC is big news. Last March, when it was announced that discussions were ongoing, this stock fell from $8 to where it is now
...more
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(4)
•••
Imlearning
X
View Profile
View Bullboard History
Comment by
Imlearning
on Jun 12, 2023 12:23pm
RE:not just one but two cantechletter.com articles
Thanks for posting this.
(1909)
•••
Possibleidiot01
X
View Profile
View Bullboard History
Post by
Possibleidiot01
on Jun 12, 2023 6:48am
not just one but two cantechletter.com articles
May provide a volume lift ? HLS Therapeutics is still a buy, says Stifel It’s been a rough ride these past two years for fans of specialty pharma company HLS Therapeutics (HLS Therapeutics
...more
(31)
•••
Pat123
X
View Profile
View Bullboard History
Post by
Pat123
on May 10, 2023 2:23pm
Dividend
Expecting a dividend cut tomorrow. Poorly managed co. avoid at all cost
(24)
•••
microcaptt
X
View Profile
View Bullboard History
Comment by
microcaptt
on Apr 17, 2023 3:39pm
RE:Anyone following HLS still?
IMO the stock is dirt cheap. Valuation is less now than when they went public. At that time the stock valuation was primarily to the Cloz asset - they didnt even know they had a
...more
(10)
•••
rational
X
View Profile
View Bullboard History
Post by
rational
on Apr 17, 2023 2:08pm
Anyone following HLS still?
BB activity really petered out here. I am still curious about this company, and I note some analysts are still expecting big things from HLS. Thoughts anyone?
(6026)
•••
retiredcf
X
View Profile
View Bullboard History
Post by
retiredcf
on Apr 28, 2022 7:00am
Clarus Revise Target
4/27/2022 Clarus Securities Reiterated Rating Buy C$26.50
(6026)
•••
retiredcf
X
View Profile
View Bullboard History
Post by
retiredcf
on Mar 22, 2022 6:58am
Clarus
HLS Therapeutics Reiterated by Clarus Securities C$33.00 Buy
(6026)
•••
retiredcf
X
View Profile
View Bullboard History
Post by
retiredcf
on Mar 18, 2022 8:19am
Canaccord
Still looking for a double. GLTA Canaccord Genuity’s Tania Armstrong-Whitworth lowered her HLS Therapeutics Inc. target by 25 cents to $30.50 with a “buy” rating. The average is $30.58.
(6026)
•••
retiredcf
X
View Profile
View Bullboard History
Post by
retiredcf
on Mar 17, 2022 9:14am
NR
08:20 AM EDT, 03/17/2022 (MT Newswires) -- HLS Therapeutics Inc. (HLS.TO), a pharmaceutical company focusing on central nervous system and cardiovascular markets, on Thursday reported, in US$, that Q4
...more
(6026)
•••
retiredcf
X
View Profile
View Bullboard History
Post by
retiredcf
on Dec 21, 2021 12:45pm
More Good Looking Targets
A very illiquid stock and a very quiet BB but now might be the time to start paying attention. GLTA HLS THERAPEUTICS (TSE:HLS) ANALYST RATINGS HISTORY 12/16/2021 Raymond James
...more
(6026)
•••
retiredcf
X
View Profile
View Bullboard History
Post by
retiredcf
on Dec 21, 2021 12:42pm
Canaccord 2022 Top Picks
Reopening and public access to bring the pulse back Investment recommendation HLS is a specialty pharma company focused on bringing innovative central nervous system (CNS) and
...more
(3214)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Aug 16, 2021 6:44am
Promotional Agreement with Pfizer for Vascepa® in Canada
Agreement enables rapid, efficient and impactful expansion to the primary care physician audience. HLS will continue to focus primarily on specialists while Pfizer will focus primarily on primary
...more
(277)
•••
wannabebuffet
X
View Profile
View Bullboard History
Comment by
wannabebuffet
on Mar 17, 2021 5:35pm
RE:Q FOUR tomorrow before sunrise!
I was tempted to move out of my position into something else but with the predictions of the analysts I decided to stay in. It has made me a lot of money over the years so a few more to see how
...more
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >